VRI to use Proteome Systems platform to develop diagnostics

By Melissa Trudinger
Wednesday, 27 November, 2002

VRI BioMedical and Proteome Systems have signed a non-binding heads of agreement for a collaboration to develop some of VRI's diagnostic tests as point-of-care applications using Proteome Systems' proprietary diagnostic test platform.

"We have IP for a range of diagnostic tests which are ideal for point-of-care applications," explained VRI chief operating officer Dr Peter French.

He said the company had developed a number of lab-based diagnostic tests for a variety of medical conditions, including cancer.

"We have a couple of commercial partners interested in our diagnostic technology if we can supply it as a point-of-care diagnostic, and Proteome Systems has an appropriate rapid diagnostic platform," French said.

Leon Ivory, executive chairman of VRI, said that the agreement would accelerate commercialisation of VRI's diagnostic program and would generate significant commercial benefits to both companies.

French said that while details of the project were still confidential, co-development of the tests had already commenced. He said that a binding agreement would probably be in place in a few weeks.

Related News

Victoria detects H5N1 avian influenza strain

It follows disease confirmation in seabirds in WA, SA, NSW and Qld and the national decision that...

TGA acts on melatonin imports with infringement notices totalling $99K

Laboratory testing of several imported unregistered melatonin products has confirmed them to be...

Scientists search for cystitis pain 'off switch'

By targeting certain pain receptors in the bladder, Australian scientists believe that the...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd